Negative dimension stability across clinical stages and sociodemographic characteristics in schizophrenia.

Competing Interests: BO has been a consultant for and received honoraria from Janssen-Cilag. CN has been a consultant and/or advisor or has received honoraria from Ache, Daiichi-Sankyo, Janssen, and Lundbeck. HE has received honoraria for participating in advisory boards and speaking/travel support from the following pharmaceutical companies: Aché, Cristalia, Daiichi-Sankyo, Janssen, Mantecorp-Hypera, Sandoz, and Teva. RB reports personal income from Torrent, Ludbeck, and Ache, as well as personal income and non-financial support from Janssen outside this research project. The other authors report no conflicts of interest.